Inhibitors were administered based on established doses of efficacy found in previous studies. Animals were treated with 2.5 μg of anti-CSF-1R neutralizing antibody (cat# NBP1–43363, clone AFS98, Novus Biologicals, Centennial, CO, USA), or antibody isotype control (cat# 554682, IgG K isotype control, BD Pharmingen, Franklin Lakes, NJ, USA) was administered by tail vein i.v. four hours before termination of the experiment as previously described (27 (link)). For in vitro studies, GW2580 a small molecule inhibitor of CSF-1R (cat# G-5903, LC Laboratories, Woburn, MA, USA) was dissolved in DMSO was used at a concentration of 100 nM, and anti-CSF-1R neutralizing antibody or isotype control (clone AFS98, Novus Biologicals) was used at a concentration of 50 ng/mL
Surve C.R., Duran C.L., Ye X., Chen X., Lin Y., Harney A.S., Wang Y., Sharma V.P., Stanley E.R., Cox D., McAuliffe J.C., Entenberg D., Oktay M.H, & Condeelis J.S. (2024). Signaling events at TMEM doorways provide potential targets for inhibiting breast cancer dissemination. bioRxiv.
+ Open protocol